Table 3.
Preclinical study with novel molecular targeted therapies as RSs in HCC
| Agent | Target | Cell Line | Animal Model | References |
|---|---|---|---|---|
| AR-42 | HDAC inhibitors | Huh-7 and PLC-5 | Ectopic and orthotopic xenografts | [6] |
| VE-465 | Aurora kinase inhibitor | Huh-7 and PLC-5 | Ectopic and orthotopic xenografts | [7] |
| BKM120 | PI3K inhibitor | Huh-7 and BNL | Ectopic xenografts | [8] |
| SC-59 | Sorafenib derivative and SHP-1 agonist | SK-Hep1, Hep3B, and Huh-7 | Ectopic xenografts | [9] |
| ANI | PARP-1 inhibitor | HepG2 | In vitro study | [42] |
| Sorafenib | Multiple kinases inhibitor | PLC-5, Huh-7, Sk-Hep1, and Hep3B | Ectopic xenografts | [37] |
| Sorafenib | Multiple kinases inhibitor | SMMC-7721 and SK-Hep1 | Ectopic xenografts | [38] |
Huh-7=human hepatoma cell line; PLC-5=PLC/PRF/5; BNL=BNL CL.2; SK-Hep1=an immortal, human cell line derived from the ascetic fluid of a patient with adenocarcinoma of the live; Hep3B=Hep 3B2.1-7; HepG2=liver hepatocellular cells; SMMC-7721=human hepatocellular carcinoma cell line; PARP-1=Poly (ADP-ribose) polymerase-1.